Insulet sees momentum, raises outlook
By HME News Staff
Updated 11:55 AM CDT, Thu May 7, 2026
ACTON, Mass. – Insulet reported revenue of $761.7 million for the first quarter of 2026, an increase of 33.9% over the prior year. Total Omnipod revenue was $758.4 million, up 36.9%. Of that, U.S. Omnipod revenue was $515.6 million and international Omnipod revenue was $242.9 million.
“We started the year strong, delivering continued growth momentum and robust operating margin expansion in the first quarter,” said Ashley McEvoy, president and CEO. “Our team executed on our strategic priorities, growing our global Podder community and strengthening our leadership in the AID market, and we are raising our total company revenue growth outlook to reflect our progress. We are confident in our ability to achieve our long‑term growth objectives by accelerating innovation, developing our markets, strengthening our commercial engine, and scaling our global operations.”
Recent strategic highlights:
- Launched Omnipod 5 and Omnipod Discover in five countries in the Middle East, bringing Omnipod 5 availability to 19 countries
- Completed a U.S. limited market release of Omnipod 5 algorithm with FreeStyle Libre 3 Plus, further broadening sensor connectivity across leading CGM platforms
- Repurchased 1.25 million shares of common stock
Comments